Published in Blood Coagul Fibrinolysis on January 01, 2009
Pain and pain management in haemophilia. Blood Coagul Fibrinolysis (2016) 0.75
Beyond stopping the bleed: short-term episodic prophylaxis with recombinant activated factor FVII in haemophilia patients with inhibitors. Blood Transfus (2015) 0.75
Bayesian approach to the assessment of the population-specific risk of inhibitors in hemophilia A patients: a case study. J Blood Med (2016) 0.75
Diversity of CTX-M beta-lactamases and their promoter regions from Enterobacteriaceae isolated in three Parisian hospitals. FEMS Microbiol Lett (2002) 4.36
Contribution of acquired carbapenem-hydrolyzing oxacillinases to carbapenem resistance in Acinetobacter baumannii. Antimicrob Agents Chemother (2005) 3.41
Plasmid-mediated high-level resistance to aminoglycosides in Enterobacteriaceae due to 16S rRNA methylation. Antimicrob Agents Chemother (2003) 3.22
Expression of the RND-type efflux pump AdeABC in Acinetobacter baumannii is regulated by the AdeRS two-component system. Antimicrob Agents Chemother (2004) 2.89
ColE1-like plasmid pIP843 of Klebsiella pneumoniae encoding extended-spectrum beta-lactamase CTX-M-17. Antimicrob Agents Chemother (2002) 2.21
AdeIJK, a resistance-nodulation-cell division pump effluxing multiple antibiotics in Acinetobacter baumannii. Antimicrob Agents Chemother (2007) 2.04
Distribution of extended-spectrum beta-lactamases in clinical isolates of Enterobacteriaceae in Vietnam. Antimicrob Agents Chemother (2002) 1.94
Overexpression of resistance-nodulation-cell division pump AdeFGH confers multidrug resistance in Acinetobacter baumannii. Antimicrob Agents Chemother (2010) 1.58
Hemophilia A induced by ipilimumab. N Engl J Med (2011) 1.55
Acquired hemophilia in older people: a poor prognosis despite intensive care. J Am Geriatr Soc (2007) 1.54
Proteolytic antibodies activate factor IX in patients with acquired hemophilia. Blood (2010) 1.53
RmtF, a new member of the aminoglycoside resistance 16S rRNA N7 G1405 methyltransferase family. Antimicrob Agents Chemother (2012) 1.49
Sequence of conjugative plasmid pIP1206 mediating resistance to aminoglycosides by 16S rRNA methylation and to hydrophilic fluoroquinolones by efflux. Antimicrob Agents Chemother (2008) 1.44
Transfer of vancomycin resistance transposon Tn1549 from Clostridium symbiosum to Enterococcus spp. in the gut of gnotobiotic mice. Antimicrob Agents Chemother (2006) 1.43
GES-11, a novel integron-associated GES variant in Acinetobacter baumannii. Antimicrob Agents Chemother (2009) 1.36
Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A. Blood (2005) 1.33
Complex genetic structures with repeated elements, a sul-type class 1 integron, and the blaVEB extended-spectrum beta-lactamase gene. Antimicrob Agents Chemother (2006) 1.23
VWF protects FVIII from endocytosis by dendritic cells and subsequent presentation to immune effectors. Blood (2006) 1.20
Inhibitor development in haemophilia according to concentrate. Four-year results from the European HAemophilia Safety Surveillance (EUHASS) project. Thromb Haemost (2015) 1.20
Integron-associated antibiotic resistance in Salmonella enterica serovar typhi from Asia. Antimicrob Agents Chemother (2003) 1.16
Native valve endocarditis due to Enterococcus hirae. J Clin Microbiol (2002) 1.15
Immune tolerance induction in patients with severe hemophilia with inhibitors: expert panel views and recommendations for clinical practice. Eur J Haematol (2012) 0.98
The interaction between factor H and VWF increases factor H cofactor activity and regulates VWF prothrombotic status. Blood (2013) 0.93
Aminoglycoside resistance gene ant(4')-IIb of Pseudomonas aeruginosa BM4492, a clinical isolate from Bulgaria. Antimicrob Agents Chemother (2003) 0.92
The cme gene of Clostridium difficile confers multidrug resistance in Enterococcus faecalis. FEMS Microbiol Lett (2004) 0.91
Clostridium clostridioforme and Atopobium minutum clinical isolates with vanB-type resistance in France. J Clin Microbiol (2011) 0.88
The functional vanGCd cluster of Clostridium difficile does not confer vancomycin resistance. Mol Microbiol (2013) 0.88
Analysis of the mobilization functions of the vancomycin resistance transposon Tn1549, a member of a new family of conjugative elements. J Bacteriol (2009) 0.88
Protein A Sepharose immunoadsorption can restore the efficacy of platelet concentrates in patients with Glanzmann's thrombasthenia and anti-glycoprotein IIb-IIIa antibodies. Br J Haematol (2002) 0.87
Inhibition of fibrinolysis by recombinant factor VIIa in plasma from patients with severe hemophilia A. Blood (2002) 0.87
Distribution of the vanG-like gene cluster in Clostridium difficile clinical isolates. Can J Microbiol (2012) 0.85
Circulating microparticles are elevated in haemophiliacs and non-haemophilic individuals aged <18 years. Br J Haematol (2005) 0.85
Reappraisal of in utero stem cell transplantation based on long-term results. Fetal Diagn Ther (2004) 0.84
Safety and efficacy of sucrose-formulated full-length recombinant factor VIII: experience in the standard clinical setting. Thromb Haemost (2008) 0.84
Interest of transjugular liver biopsy in adult patients with haemophilia or other congenital bleeding disorders infected with hepatitis C virus. Br J Haematol (2004) 0.83
Beyond patient benefit: clinical development in hemophilia. Hematology (2012) 0.82
Genetic and biochemical characterization of OXA-63, a new class D beta-lactamase from Brachyspira pilosicoli BM4442. Antimicrob Agents Chemother (2008) 0.81
Factor VIII-hydrolyzing IgG in acquired and congenital hemophilia. FEBS Lett (2009) 0.81
Intestinal surgery with activated recombinant factor VII prophylaxis in patients with haemophilia A and high responding inhibitors: a report of five cases. Blood Coagul Fibrinolysis (2004) 0.81
Detection of 95 novel mutations in coagulation factor VIII gene F8 responsible for hemophilia A: results from a single institution. Hum Mutat (2006) 0.80
A novel ELISA-based diagnosis of acquired von Willebrand disease with increased VWF proteolysis. Thromb Haemost (2016) 0.80
Factor VIII hydrolysis mediated by anti-factor VIII autoantibodies in acquired hemophilia. J Immunol (2008) 0.80
PRO-PACT: retrospective observational study on the prophylactic use of recombinant factor VIIa in hemophilia patients with inhibitors. Thromb Res (2012) 0.78
Development of inhibitory antibodies to therapeutic factor VIII in severe hemophilia A is associated with microsatellite polymorphisms in the HMOX1 promoter. Haematologica (2013) 0.77
Pseudo-outbreak of Oxa-23-mediated carbapenem-resistant Acinetobacter baumannii in urinary tract infections caused by an automated urine analyzer. Infect Control Hosp Epidemiol (2014) 0.77
Emergence and dissemination of a new mechanism of resistance to aminoglycosides in Gram-negative bacteria: 16S rRNA methylation. Euro Surveill (2005) 0.76
Long-acting recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in children. Results of a phase 3 trial. Thromb Haemost (2016) 0.76
Determinants of drug costs in hopitalised patients with haemophilia: impact of recombinant activated factor VII. Pharmacoeconomics (2003) 0.76
Injection of recombinant activated factor VII can induce transient increase in circulating procoagulant microparticles. Thromb Haemost (2004) 0.75
Switching treatments in haemophilia: is there a risk of inhibitor development? Eur J Haematol (2014) 0.75
Influence of factor VIII level and its inhibitor titer on the therapeutic response to corticosteroids alone in the management of acquired hemophilia: A retrospective single-center study. Medicine (Baltimore) (2016) 0.75
Pain and pain management in haemophilia. Blood Coagul Fibrinolysis (2016) 0.75
Inhibitor development in non-severe haemophilia across Europe. Thromb Haemost (2015) 0.75
A Laboratory Phenotype/Genotype Correlation of 1167 French Patients From 670 Families With von Willebrand Disease: A New Epidemiologic Picture. Medicine (Baltimore) (2016) 0.75
Prevention and treatment of atherosclerosis in haemophilia - how to balance risk of bleeding with risk of ischaemic events. Eur J Haematol (2015) 0.75
Rationale for individualizing haemophilia care. Blood Coagul Fibrinolysis (2015) 0.75
Acquired haemophilia A associated with HIV infection: a rare disease. AIDS (2014) 0.75